Monrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity
11.9.2023 19:15:00 EEST | Business Wire | Press release
Eczacıbaşı Monrol Nuclear Products Co. (Monrol), one of the world's leading radiopharmaceutical producers, has decided to invest 35 million Euros to increase its production capacity for non-carrier-added Lutetium-177 (n.c.a. Lu-177) in response to growing global demand for this product.
Monrol, which manufactures radiopharmaceuticals meeting high quality standards at its production facilities, plans to increase its current n.c.a. Lu-177 production capacity through the expansion of existing production lines at the Monrol Gebze facility in Turkey as well as the establishment of a new production facility at the Gebze campus. The expansion project will come into operation gradually and reach full capacity by 2026.
N.c.a. Lu-177 is the radionuclide that forms the basis of targeted radioligand therapy(*), widely used today in the treatment of prostate cancer and neuroendocrine tumors and expected to be used soon to treat other cancers as well.
“Prostate cancer is the most common type of cancer in men after lung cancer, with its incidence increasing rapidly around the world. By 2040, 2.3 million new cases of prostate cancer are predicted annually worldwide. The production capacity increase at our Gebze facility in Turkey, which will comply fully with EU and US quality standards, will meet the increasing global demand for n.c.a. Lu-177. In fact, we aim to make the Gebze production facility a “center of excellence” for the production of theranostic products,” commented Aydin Kucuk, General Manager of Monrol.
(*) Targeted radioligand therapy, is an innovative approach to cancer treatment. Multiple clinical trials are investigating the effects of this treatment approach on various types of cancers across the world.
ENDS
About Monrol
Headquartered in Istanbul, Monrol is a nuclear medicine company leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals, Monrol distributes its world-class radiopharmaceutical products portfolio in global markets. As both a CMO and CDMO, Monrol provides early development support to customers and offers fully integrated services for nimble, lean, virtual companies taking new product concepts into clinical trials, demonstrating proof of concept, and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment through a portfolio of radiopharmaceutical products that it distributes to more than 60 countries around the globe. To learn more, visit www.monrol.com and LinkedIn.
About n.c.a. Lutetium-177
Lutetium-177 n.c.a. is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a. enables treatment options that have the potential today to improve treatment outcomes for certain cancer patients and may soon offer improved treatment options for others, thanks to ongoing clinical development. The unique properties of Lu-177 n.c.a. make it a desirable radioisotope for peptide receptor radionuclide therapy (PRRT) used to treat certain cancers like Neuro Endocrine Tumors (NET) and Prostate cancer. Monrol n.c.a. Lutetium-177 DMF has been listed by the FDA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911648623/en/
Contact information
For further information please contact:
Monrol
Aydın Küçük
General Manager
monrol@monrol.com
Media Enquiries
Alkim Aydın
Marketing Manager
alkim.aydin@monrol.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 13:45:00 EEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time building and updating planograms and more time acting on opportunities. With greater automation, retailers can improve productivi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom